Business
-
CDMO and device maker Recipharm has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as a member, the company announced. Recipharm will be represented on the IPAC-RS Board by Head of Commercial… Read more . . .
-
Startup Moat Biotechnology announced the initiation of a funding round led by Cortado Ventures that aims to raise up to $20 million for continued development of the company’s intranasal vaccine against COVID-19. According to the… Read more . . .
-
The US Department of Justice has announced that Akorn will pay $7.9 million to settle a case related to submission of false claims to Medicare Part D after the company continued to sell three products,… Read more . . .
-
Yale University spinout RIGImmune, which has been developing stemloop RNA (SLR) therapeutics, announced that it has acquired biotech Subintro, which has been working on antivirals for RNA virus-caused respiratory infections. The company will now develop… Read more . . .
-
According to Tiziana Life Sciences, The ALS Association will award a Lawrence & Isabel Barnett Drug Development Program Grant to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital (BWH) for… Read more . . .
-
Nebulizer developer Respira Technologies, which recently announced the appointment of Brian Quigley as CEO, has changed its name to “Qnovia,” the company said. No reason for the name change was announced, but the previous name… Read more . . .
-
Illiad Biotechnologies has closed a $42.8 million financing round, the company said, with the funds intended to support a Phase 2b challenge study of the company’s BPZE1 intranasal pertussis vaccine as well as other development… Read more . . .
-
The United States District Court for the District of Delaware has ruled that Liquidia’s Yutrepia treprostinil DPI would infringe claims contained in US patents 9,593,066 and 10,716,793, which cover United Therapeutics’ Tyvaso inhaled treprostinil; however,… Read more . . .
-
The European Patent Office (EPO) has granted Orexo a patent (EP 3962455B1) covering the company’s OX640 intranasal dry powder adrenaline, which is in Phase 1 development for the emergency treatment of anaphylaxis. According to the… Read more . . .
-
Hikma Pharmaceuticals has launched Ryaltris olopatadine / mometasone nasal spray in the US, the company said. Hikma acquired US rights to Ryaltris in February 2020, and the FDA approved Glenmark’s NDA for the nasal spray… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK